title: Vitreous opacities and outcome of vitreous surgery in patients with familial amyloidotic polyneuropathy.
abstract: OBJECTIVE
  To report the prevalence of vitreous opacities and the outcome of vitreous surgery in patients with familial amyloidotic polyneuropathy (FAP).
  
  
  METHODS
  Observational case series.
  
  
  METHODS
  In 37 patients with FAP and the ATTR Val30 Met mutation, vitreous opacities were present in 14 eyes of 9 patients and vitrectomy combined with phacoemulsification and intraocular lens implantation was performed in five eyes of three patients. In six patients with the ATTR Tyr114Cys mutation, vitreous opacities were present in both eyes of all six patients and vitrectomy combined with phacoemulsification and intraocular lens implantation was performed in nine eyes of six patients. The mean follow-up period after vitreous surgery was 20.9 +/- 16.8 months (range, 3 to 52 months).
  
  
  RESULTS
  The prevalence of vitreous opacities is much higher in patients with ATTR Tyr114Cys (100%) than in those with ATTR Val30 Met (24%). The mean age at the onset of vitreous opacities was significantly lower in the patients with ATTR Tyr114Cys (37.0 +/- 5.3 years) than in the nine patients with ATTR Val30 Met (52.8 +/- 9.1 years; P <.005). Visual acuity improved in all 14 eyes after vitreous surgery; however, final visual acuity decreased in one eye owing to the occurrence of a central retinal vein occlusion. Vitreous opacities mildly increased in two eyes.
  
  
  CONCLUSIONS
  Our data suggest that the ATTR Val30 Met and ATTR Tyr114Cys mutations induce different clinical features of vitreous opacities. Vitreous surgery combined with phacoemulsification and implantation of an intraocular lens is a safe and useful treatment. Careful long-term follow-up should be performed.
authors.affiliation: Department of Ophthalmology, Kumamoto University School of Medicine, Kumamoto, Japan. 994m9031@med.stud.kumamoto-u.ac.jp
authors.forename: Takahisa
authors.initials: T
authors.lastname: Koga
authors.forename: Eiko
authors.initials: E
authors.lastname: Ando
authors.forename: Akira
authors.initials: A
authors.lastname: Hirata
authors.forename: Mikiko
authors.initials: M
authors.lastname: Fukushima
authors.forename: Akira
authors.initials: A
authors.lastname: Kimura
authors.forename: Yukio
authors.initials: Y
authors.lastname: Ando
authors.forename: Akira
authors.initials: A
authors.lastname: Negi
authors.forename: Hidenobu
authors.initials: H
authors.lastname: Tanihara
mesh_terms: D000328:Adult; D000368:Aged; D000682:Amyloid / Q000235:genetics; D028227:Amyloid Neuropathies, Familial / Q000150:complications* / Q000235:genetics / Q000601:surgery; D005128:Eye Diseases / Q000209:etiology* / Q000601:surgery*; D005260:Female; D006801:Humans; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D011228:Prealbumin / Q000235:genetics; D015995:Prevalence; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy; D014822:Vitreous Body / Q000473:pathology*
chemical_list: D000682:Amyloid; D011228:Prealbumin; C041120:amyloid prealbumin